6B5R

Structure of PfCSP peptide 21 with human antibody CIS42


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.775 Å
  • R-Value Free: 0.237 
  • R-Value Work: 0.191 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.

Kisalu, N.K.Idris, A.H.Weidle, C.Flores-Garcia, Y.Flynn, B.J.Sack, B.K.Murphy, S.Schon, A.Freire, E.Francica, J.R.Miller, A.B.Gregory, J.March, S.Liao, H.X.Haynes, B.F.Wiehe, K.Trama, A.M.Saunders, K.O.Gladden, M.A.Monroe, A.Bonsignori, M.Kanekiyo, M.Wheatley, A.K.McDermott, A.B.Farney, S.K.Chuang, G.Y.Zhang, B.Kc, N.Chakravarty, S.Kwong, P.D.Sinnis, P.Bhatia, S.N.Kappe, S.H.I.Sim, B.K.L.Hoffman, S.L.Zavala, F.Pancera, M.Seder, R.A.

(2018) Nat. Med. 24: 408-416

  • DOI: 10.1038/nm.4512
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Development of a highly effective vaccine or antibodies for the prevention and ultimately elimination of malaria is urgently needed. Here we report the isolation of a number of human monoclonal antibodies directed against the Plasmodium falciparum (P ...

    Development of a highly effective vaccine or antibodies for the prevention and ultimately elimination of malaria is urgently needed. Here we report the isolation of a number of human monoclonal antibodies directed against the Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP) from several subjects immunized with an attenuated Pf whole-sporozoite (SPZ) vaccine (Sanaria PfSPZ Vaccine). Passive transfer of one of these antibodies, monoclonal antibody CIS43, conferred high-level, sterile protection in two different mouse models of malaria infection. The affinity and stoichiometry of CIS43 binding to PfCSP indicate that there are two sequential multivalent binding events encompassing the repeat domain. The first binding event is to a unique 'junctional' epitope positioned between the N terminus and the central repeat domain of PfCSP. Moreover, CIS43 prevented proteolytic cleavage of PfCSP on PfSPZ. Analysis of crystal structures of the CIS43 antigen-binding fragment in complex with the junctional epitope determined the molecular interactions of binding, revealed the epitope's conformational flexibility and defined Asn-Pro-Asn (NPN) as the structural repeat motif. The demonstration that CIS43 is highly effective for passive prevention of malaria has potential application for use in travelers, military personnel and elimination campaigns and identifies a new and conserved site of vulnerability on PfCSP for next-generation rational vaccine design.


    Organizational Affiliation

    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
CIS42 Fab Heavy chain
H
222N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
CIS42 Fab Light chain
L
216N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
PfCSP peptide 21: ASN-PRO-ASP-PRO-ASN-ALA-ASN-PRO-ASN-VAL-ASP-PRO-ASN
A
15Plasmodium falciparumMutation(s): 0 
Find proteins for P02893 (Plasmodium falciparum)
Go to UniProtKB:  P02893
Small Molecules
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
PCA
Query on PCA
H
L-PEPTIDE LINKINGC5 H7 N O3GLU
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.775 Å
  • R-Value Free: 0.237 
  • R-Value Work: 0.191 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 41.131α = 90.00
b = 70.570β = 90.00
c = 165.379γ = 90.00
Software Package:
Software NamePurpose
PHASERphasing
HKL-2000data reduction
PHENIXrefinement
HKL-2000data scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2018-03-21
    Type: Initial release
  • Version 1.1: 2018-04-04
    Type: Data collection, Database references
  • Version 1.2: 2018-04-25
    Type: Data collection, Database references